CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair.
Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His input will be critical to CorneaGen’s success in developing the next generation of cornea care to eliminate corneal blindness worldwide, starting with Cornea Cell Therapy Transplantation, according to a company news release. Former board chair Dr. Bill Link and CorneaGen President and CEO Monty Montoya led the process to recruit Tom. Dr. Link will remain a key member of CorneaGen’s board of directors.
“Tom’s deep experience in bringing ophthalmology products to market and maximizing market potential is great for CorneaGen—he will have an active role in company strategy and development,” said Mr. Montoya. “Our leadership team is looking forward to leveraging his advice as we continue to develop CorneaGen into a customer-centric, revenue-generating engine to power our mission.”
Mr. Frinzi recently retired from his position as worldwide president of Johnson & Johnson Vision, Surgical.
“I have devoted my career to building companies that improve the vision—and lives—of people around the world,” said Mr. Frinzi. “CorneaGen is a purpose-driven organization, which is consistent with how I have managed my career, and I am excited to help them achieve their mission of eliminating corneal blindness by 2040.
Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. He served as president and CEO of WaveTec Vision, a developer of intraoperative aberrometry for cataract surgery. Mr. Frinzi built the WaveTec business by fundamentally changing product development, go-to-market strategies and customer value propositions, resulting in a sale to Alcon in 2014. He also held senior positions in commercial operations, business development and sales and marketing at Bausch & Lomb Surgical, Refractec and Johnson & Johnson.